|
Isobutyryl-CoA dehydrogenase deficiency
|
0.730 |
GeneticVariation
|
disease |
BEFREE |
Isobutyryl-CoA dehydrogenase deficiency with a novel ACAD8 gene mutation detected by tandem mass spectrometry newborn screening.
|
17924841 |
2007 |
|
Isobutyryl-CoA dehydrogenase deficiency
|
0.730 |
Biomarker
|
disease |
BEFREE |
Our results broaden the mutational spectrum of ACAD8 and improve the understanding of the clinical phenotype of IBDHD.
|
30253142 |
2018 |
|
Isobutyryl-CoA dehydrogenase deficiency
|
0.730 |
Biomarker
|
disease |
BEFREE |
The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschütter-Tönz syndrome).
|
25111118 |
2014 |
|
Anemia
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of Anemia in Pediatric IBD Patients and Impact on Disease Severity: Results of the Pediatric IBD-Registry CEDATA-GPGE®.
|
29358946 |
2017 |
|
Anemia
|
0.160 |
Biomarker
|
disease |
BEFREE |
Anaemia is an important complication of inflammatory bowel disease [IBD].
|
28575481 |
2017 |
|
Anemia
|
0.160 |
Biomarker
|
disease |
BEFREE |
Anaemia is common in patients with inflammatory bowel disease [IBD], its two main aetiologies being iron deficiency anaemia [IDA] and anaemia of chronic inflammation [ACI].
|
31665264 |
2020 |
|
Anemia
|
0.160 |
Biomarker
|
disease |
BEFREE |
Clinicians should strongly consider investigation for IBD in young patients presenting with diarrhoea and anaemia [in males] following PA. Future research should discern appropriate screening strategies for this high-risk cohort.
|
30544202 |
2019 |
|
Anemia
|
0.160 |
Biomarker
|
disease |
BEFREE |
Expert commentary: Anemia in IBD is polyetiological, reaching far beyond iron deficiency anemia.
|
27885843 |
2017 |
|
Anemia
|
0.160 |
Biomarker
|
disease |
BEFREE |
Ferinject®-therapy was proven to be effective and safe in a large cohort of patients with IBD-associated anaemia in routine practice.
|
29955835 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, outcome from our current studies identifies Cld-1 as potential prognostic biomarker for IBD severity and CAC, and a novel therapeutic target.
|
30971761 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Alterations in mitochondrial function and MT-UPR activation are integral aspects of pathologies, including IBD and cancer.
|
29844587 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Korean patients with IBD are at increased risk for overall, intestinal and haematological cancer.
|
28333358 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Considering the high risk of dysplasia and cancer in inflammatory bowel disease [IBD], surveillance is advocated.
|
30597029 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The registries included those falling within the remit of national statistics, hospital databases, twin and multiplex registries, inflammatory bowel disease [IBD] registries and biobanks, and cancer and surgical registries.
|
28158624 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CRC was not observed in our cohort.The six extraintestinal malignancies did not show significant relation to IBD.
|
29147110 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aims of the study were to determine the prevalence of intestinal/extraintestinal cancers in an IBD cohort 20 years after diagnosis and to assess whether these patients had an increased cancer-specific risk compared with a matched control population.
|
28453756 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest possible roles of TP53 and KRAS as biomarkers for cancer and dysplasia screening among patients with IBD and may also provide targeted therapy in patients with IBD-CRC.
|
28077799 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further studies are needed to explore the impact of comorbid conditions on the risk of cancer in IBD.
|
30874294 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among 75 patients with active IBD and PSC treated with vedolizumab, 21 patients discontinued vedolizumab before Week 30 [due to lack of efficacy in 19 and malignancy in two patients].
|
31056693 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer risk in IBD: how to diagnose and how to manage DALM and ALM.
|
21912466 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results were stratified by malignancy or IBD.
|
31318768 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IBD-CRN cases included 17 with ulcerative colitis (UC) and two with Crohn's disease (CD); nine had cancer and 10 had dysplasia.
|
23347191 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The extent of lymph node harvesting during surgery for colorectal neoplasm [dysplasia and/or cancer] complicating inflammatory bowel disease [IBD] is a matter of debate.
|
28369422 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, mTOR pathway was activated in IBD but not in CAC.
|
25569743 |
2015 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here we define the in vivo role of BVES in colitis-associated cancer (CAC), its cellular function and its relevance to patients with IBD.
|
28389570 |
2017 |